Evidence map›Paper›PMID 34698150›Full record

ArticleGels (Basel, Switzerland)2021

Matured Myofibers in Bioprinted Constructs with In Vivo Vascularization and Innervation.

Catherine G Y Ngan, Anita Quigley, Richard J Williams, Cathal D O'Connell, Romane Blanchard, Mitchell Boyd-Moss, Tim D Aumann, Penny McKelvie, Gordon G Wallace, Peter F M Choong and 1 more

Open access · goldAbstract read
In one paragraph

Article in Gels (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Catherine G Y NganDepartment of Surgery, The University of Melbourne, St Vincent's Hospital, Melbourne, VIC 3010, Australia.ORCID 0000-0003-0009-6447
Anita QuigleyARC Centre of Excellence for Electro Materials Science, University of Melbourne, Melbourne, VIC 3010, Australia.
Richard J WilliamsBiofab3D@ACMD, St Vincent's Hospital, Melbourne, VIC 3010, Australia.ORCID 0000-0003-3831-8738
Cathal D O'ConnellBiofab3D@ACMD, St Vincent's Hospital, Melbourne, VIC 3010, Australia.
Romane BlanchardDepartment of Surgery, The University of Melbourne, St Vincent's Hospital, Melbourne, VIC 3010, Australia.
Mitchell Boyd-MossSchool of Engineering, RMIT University, Bundoora, VIC 3000, Australia.ORCID 0000-0002-8670-8477
Tim D AumannFlorey Institute of Neuroscience and Mental Health, Parkville, VIC 3052, Australia.
Penny McKelvieDepartment of Anatomical Pathology, St Vincent's Hospital, Melbourne, VIC 3010, Australia.
Gordon G WallaceARC Centre of Excellence for Electro Materials Science, University of Melbourne, Melbourne, VIC 3010, Australia.ORCID 0000-0002-0381-7273
Peter F M ChoongDepartment of Surgery, The University of Melbourne, St Vincent's Hospital, Melbourne, VIC 3010, Australia.ORCID 0000-0002-3522-7374
Rob M I KapsaARC Centre of Excellence for Electro Materials Science, University of Melbourne, Melbourne, VIC 3010, Australia.
The University of Melbourne · AUDeakin University · AUSt Vincent's Hospital Melbourne · AUFlorey Institute of Neuroscience and Mental Health · AU

Funding

ARC Centre of Excellence for Electromaterials Science 140100012National Health and Medical Research Council 1133271National Health and Medical Research Council 1154203National Health and Medical Research Council 2002773
6 · The paper itself

Abstract

For decades, the study of tissue-engineered skeletal muscle has been driven by a clinical need to treat neuromuscular diseases and volumetric muscle loss. The in vitro fabrication of muscle offers the opportunity to test drug-and cell-based therapies, to study disease processes, and to perhaps, one day, serve as a muscle graft for reconstructive surgery. This study developed a biofabrication technique to engineer muscle for research and clinical applications. A bioprinting protocol was established to deliver primary mouse myoblasts in a gelatin methacryloyl (GelMA) bioink, which was implanted in an in vivo chamber in a nude rat model. For the first time, this work demonstrated the phenomenon of myoblast migration through the bioprinted GelMA scaffold with cells spontaneously forming fibers on the surface of the material. This enabled advanced maturation and facilitated the connection between incoming vessels and nerve axons in vivo without the hindrance of a scaffold material. Immunohistochemistry revealed the hallmarks of tissue maturity with sarcomeric striations and peripherally placed nuclei in the organized bundles of muscle fibers. Such engineered muscle autografts could, with further structural development, eventually be used for surgical reconstructive purposes while the methodology presented here specifically has wide applications for in vitro and in vivo neuromuscular function and disease modelling.

Indexed as

bioprintingGelMAneuromuscularskeletal muscletissue engineering

Identifiers

PMID34698150
PMCPMC8544540
OpenAlexW3206954394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.